NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Neukio Biotherapeutics

Neukio Biotherapeutics

Private
ShanghaiHealthcare & Life Scienceshttps://neukio.com/

Last Round

Series A

Sep 2, 2022

Total Funding Raised

$90M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Neukio Biotherapeutics is a biotechnology company that develops iPSC-derived cell technology platforms and next-generation off-the-shelf immune cell products for treating solid tumors and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

allogeneic cell therapyoff-the-shelf cell therapyiPSC platformCAR-NK cell therapyCAR-T cell therapyimmune cell therapyinduced pluripotent stem cellsiPSC-derived CAR-NKiPSC-derived CAR-Timmunotherapysolid tumorsautoimmune diseasesclinical-stage biotechcell therapy manufacturinggene editingGMP manufacturingin vivo CAR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neukio Biotherapeutics Comparables

Compare Neukio Biotherapeutics with similar companies based on industry and business-model similarity.

Neukio Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CellOrigin Biotech
89%
Therabest
88%
Shoreline Biosciences
84%

Neukio Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 2, 2022
AngelJul 29, 2021

Neukio Biotherapeutics Investors

Notable investors and investment history

Neukio Biotherapeutics investors
InvestorRounds
Alwin CapitalSeries A
IDG CapitalAngel, Series A
Lilly Asia VenturesSeries A, Angel
Sherpa Healthcare PartnersSeries A
CD CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 5, 2026

    Monthly visitors increased 137% MoM.

  • Nov 9, 2025

    Monthly visitors increased 531% MoM to 1.6K.

Neukio Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neukio Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neukio Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range14
Year Founded2021
Last FundingSep 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.